GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Cash Flow from Operations

Science 37 Holdings (Science 37 Holdings) Cash Flow from Operations : $-48.19 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Sep. 2023, Science 37 Holdings's Net Income From Continuing Operations was $-13.92 Mil. Its Depreciation, Depletion and Amortization was $0.16 Mil. Its Change In Working Capital was $4.16 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $5.53 Mil. Its Stock Based Compensation was $3.58 Mil. And its Cash Flow from Others was $0.09 Mil. In all, Science 37 Holdings's Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.40 Mil.


Science 37 Holdings Cash Flow from Operations Historical Data

The historical data trend for Science 37 Holdings's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Science 37 Holdings Cash Flow from Operations Chart

Science 37 Holdings Annual Data
Trend Jun20 Jun21 Dec22
Cash Flow from Operations
- -0.58 -75.44

Science 37 Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.02 -15.07 -19.61 -13.11 -0.40

Science 37 Holdings Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Science 37 Holdings's Cash Flow from Operations for the fiscal year that ended in Dec. 2022 is calculated as:

Science 37 Holdings's Cash Flow from Operations for the quarter that ended in Sep. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Science 37 Holdings  (NAS:SNCE) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Science 37 Holdings's net income from continuing operations for the three months ended in Sep. 2023 was $-13.92 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Science 37 Holdings's depreciation, depletion and amortization for the three months ended in Sep. 2023 was $0.16 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Science 37 Holdings's change in working capital for the three months ended in Sep. 2023 was $4.16 Mil. It means Science 37 Holdings's working capital increased by $4.16 Mil from Jun. 2023 to Sep. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Science 37 Holdings's cash flow from deferred tax for the three months ended in Sep. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Science 37 Holdings's cash from discontinued operating Activities for the three months ended in Sep. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Science 37 Holdings's asset impairment charge for the three months ended in Sep. 2023 was $5.53 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Science 37 Holdings's stock based compensation for the three months ended in Sep. 2023 was $3.58 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Science 37 Holdings's cash flow from others for the three months ended in Sep. 2023 was $0.09 Mil.


Science 37 Holdings Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Science 37 Holdings (Science 37 Holdings) Business Description

Traded in Other Exchanges
N/A
Address
800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709
Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Executives
Troy Bryenton officer: Chief Technology Officer 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari officer: Chief Legal Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von director BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton officer: Chief Commercial Officer 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman officer: Chief Delivery Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman director, officer: Chief Executive Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar officer: Chief Medical Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon officer: Chief Commercial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B. director PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek officer: Chief Financial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc. 10 percent owner 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331